Intellipharmaceutics International Inc.
|Company Name||Intellipharmaceutics International Inc.|
|Class Period||July 28, 2017 to -|
|Lead Plaintiff Motion Deadline||July 28, 2017|
On July 26, 2017, Intellipharmaceutics disclosed that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (“FDA”) voted 22 to 1 against approval the Company’s New Drug Application for Rexista, an opioid painkiller. The FDA committees also voted that Rexista had not demonstrated properties than can be expected to deter abuse by the intravenous route, and that there was insufficient data to support inclusion of language regarding abuse-deterrent properties in the product label for the intravenous route of administration.
On this news, the Company’s share price fell $1.13 per share, or 45.3% on July 27, 2017, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Intellipharmaceutics International Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.